Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib in renal impairment
NCT05469100Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Primary completion
- Aug 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of selpercatinib (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration at 168 hours, Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity at 168 hours and 15 more. Started Dec 2018; status: completed.
02
Drugs
selpercatinib
Beyond the preview
Go deeper on NCT05469100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469100.